A potential first-in-class pruritus treatment Cara Therapeutics is developing a peripherally acting kappa opioid receptor (KOR) agonist called difelikefalin. Difelikefalin is currently being studied in ongoing clinical trials for multiple indications. See our pipeline References: 1. Spencer R, Lewis M, Stauffer J, Mathur M, Menzaghi F. Anti-pruritic effect of the long-acting peripheral kappa opioid receptor agonist CR845: a novel approach for the treatment of uremic pruritus in hemodialysis patients. Presented at Kidney Week 2016; November 15-20, 2016; Chicago, IL. 2. Spencer R, Gardell L, Desai R, Menzaghi F. Anti-inflammatory effects of the peripheral kappa opioid receptor agonist CR845: a novel approach for the treatment of inflammatory disease. Presented at IASP 2010; September 3, 2010; Montreal, Canada. HOME WHAT WE DO FOR PATIENTS WHO WE ARE NEWS & INVESTORS CONTACT ©2021 Cara Therapeutics. All rights reserved. | Privacy Policy | Sitemap | Terms of Use

Meet our board A trusted team supporting the Cara Therapeutics vision, every step of the way. Board of directors Christopher Posner Chief Executive Officer, President, and Director View Full Bio Harrison M. Bains Director View Full Bio Jeffrey L. Ives, Ph.D. Director View Full Bio Susan Shiff, Ph.D. Director View Full Bio Martin Vogelbaum Director View Full Bio HOME WHAT WE DO FOR PATIENTS WHO WE ARE NEWS & INVESTORS CONTACT ©2021 Cara Therapeutics. All rights reserved. | Privacy Policy | Sitemap | Terms of Use

Not just any clinical stage biopharmaceutical company A nimble team that is working to turn proven science into life-changing therapeutics. Management team Christopher Posner Chief Executive Officer, President, and Director View Full Bio Frédérique Menzaghi, Ph.D. Chief Scientific Officer, SVP Research & Development View Full Bio Joana Goncalves, M.D. Chief Medical Officer View Full Bio Thomas Reilly Chief Financial Officer View Full Bio Scott Terrillion General Counsel, Secretary & Chief Compliance Officer View Full Bio Eric Vandal Sr. Vice President, Commercial View Full Bio Michael E. Lewis, Ph.D. Chief Scientific Advisor View Full Bio Come work with us HOME WHAT WE DO FOR PATIENTS WHO WE ARE NEWS & INVESTORS CONTACT ©2021 Cara Therapeutics. All rights reserved. | Privacy Policy | Sitemap | Terms of Use